Investors from the US and around the world are benefiting from the opportunities afforded by Italy's emerging biotechnology sector. With a growing critical mass of labor, infrastructure and investment, Italy is home to more than 220 biotech companies and a sector workforce of 26,000. These firms are exceptionally strong in product development, with 77 new compounds in clinical trial. Italy is also a leading market for such products, ranking fifth in the world for Pharmaceuticals and third in Europe for biotech. These attributes, combined with labor costs that are up to 50% lower than other European nations, are making Italy a home away from home for US biotech investors.
展开▼
